This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Reference not found
Reference not found
Reference not found
Reference not found
Reference not found

1.

Дедов И.И., Шестакова М.В. Сахарный диабет типа 1: реалии и перспективы. М.: МИА; 2016. [Dedov II, Shestakova MV. Sakharnyi diabet tipa 1: realii i perspektivy. M.: MIA; 2016. (In Russ.)].

2.

Rowe AH, Garrison OH. Lipodystrophy: atrophy and tumefaction of subcutaneous tissue due to insulin injections. JAMA. 1932;99:16-18.

3.

Hildebrandt P. Subcutaneous absorption of insulin in insulindependent diabetic patients. Influences of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull. 1991;38(4):337-346.

4.

Hyllested-Winge J, Sparre T, Kynemund Pedersen L. NovoPen Echo® insulin delivery device. Med Devices (Auckl). 2016;9:11-18 doi: https://doi.org/10.2147/MDER.S59229.

5.

Shah R, Patel M, Maahs D, Shah V. Insulin delivery methods: Past, present and future. Int J Pharm Investig. 2016;6(1):1. doi: https://doi.org/10.4103/2230-973X.176456 

6.

Heise T, Nosek L, Ronn BB, et al. Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes. Diabetes. 2004;53(6):1614-1620. doi: http://doi.org/10.2337/diabetes.53.6.1614

7.

Дедов И.И., Шестакова М.В. Инсулин деглудек — новый аналог инсулина сверхдлительного действия // Сахарный диабет. — 2014. — Т. 17. — №2. — С. 91-104. [Dedov II, Shestakova MV. Insulin degludec is a new ultra-long-acting insulin analogue. Diabetes mellitus. 2014;17(2):91-104 (In Russ.)]. doi: https://doi.org/10.14341/DM2014291-104

8.

Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units/mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units/mL-1. Diabetes Care. 2015;38(4):637-643. doi: https://doi.org/https://doi.org/10.2337/dc14-0006

9.

Davis A, Kuriakose J, Clements JN. Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. Clin Pharmacokinet. 2019;58(4):421-430. doi: https://doi.org/10.1007/s40262-018-0696-8

10.

Дедов И.И., Балаболкин М.И. Возможности и проблемы трансплантации бета-клеток поджелудочной железы при сахарном диабете // Сахарный диабет. — 2005. — Т. 8. — №2. — С. 42-52. [Dedov II, Balabolkin MI. Vozmozhnosti i problemy transplantatsii beta-kletok podzheludochnoy zhelezy pri sakharnom diabete. Diabetes mellitus. 2005;8(2):42-52. (In Russ.)]. doi: https://doi.org/10.14341/2072-0351-5781

11.

Пеллегрини С., Сарди В., Пьемонти Л. Замещение бетаклеток поджелудочной железы при сахарном диабете // Сахарный диабет. — 2013. — Т. 16. — № 3. — С. 11-20. [Pellegrini S, Sordi V, Piemonti L. Beta-cell transplantation in diabetes mellitus. Diabetes mellitus. 2013;16(3):11-20 (In Russ.)]. doi: https://doi.org/10.14341/2072-0351-812

12.

Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009;3(1):44-55. doi: https://doi.org/10.1177/193229680900300106

13.

Kesavadev J, Saboo B, Krishna MB, et al. Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. Diabetes Ther. 2020;11:1251-1269. doi: https://doi.org/10.1007/s13300-020-0083